Literature DB >> 28455149

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base.

Amy C Moreno1, Vivek Verma2, Wayne L Hofstetter3, Steven H Lin4.   

Abstract

INTRODUCTION: This study analyzes practice patterns, treatment-related mortality, survival, and predictors thereof in elderly patients with early-stage esophageal cancer (EC).
METHODS: The National Cancer Data Base was queried for cT1-2 N0 EC in patients 80 years of age and older. Patients were divided into four treatment groups: observation (Obs), chemoradiotherapy (CRT), local excision (LE), and esophagectomy (Eso). Patient, tumor, and treatment parameters were extracted and compared. Analyses were performed on overall survival (OS) and postoperative 30- and 90-day mortality.
RESULTS: A total of 923 patients from 2004 to 2012 were analyzed. Of these, 43% underwent clinical Obs, 22% underwent CRT, 25% underwent LE, and 10% underwent Eso. Patients undergoing Obs were older, had more comorbidities, were treated at nonacademic centers, and lived 25 miles or less from the facility. Patients receiving an operation (Eso or LE) were more often younger, male, white, and in the top income quartile. The postoperative 30-day mortality rates in the LE and Eso groups were 1.3% and 9.6%, respectively (p < 0.001) and increased to 2.6% and 20.2% at 90 days, respectively (p < 0.001). The 5-year OS rate was 7% for Obs, 20% for CRT, 33% for LE, and 45% for Eso (p < 0.001). Multivariate analyses showed improved OS with any local definitive therapy: CRT (hazard ratio [HR] = 0.42, 95% confidence interval [CI]: 0.34-0.52, p < 0.001), LE (HR = 0.3, 95% CI: 0.24-0.38, p < 0.001), and Eso (HR = 0.32, 95% CI: 0.23-0.44, p < 0.001).
CONCLUSIONS: There are noteworthy demographic, socioeconomic, and regional disparities influencing management of elderly patients with stage I EC. Despite high rates of Obs, careful consideration of all local therapy options is warranted, given the improved outcomes with treatment.
Copyright © 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; Elderly; Esophageal cancer; Esophagectomy; Radiotherapy

Mesh:

Year:  2017        PMID: 28455149     DOI: 10.1016/j.jtho.2017.04.004

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  20 in total

1.  Addition of chemotherapy to hypofractionated radiotherapy for glioblastoma: practice patterns, outcomes, and predictors of survival.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Neurooncol       Date:  2017-10-31       Impact factor: 4.130

2.  Definitive chemoradiation at high volume facilities is associated with improved survival in glioblastoma.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Neurooncol       Date:  2017-07-07       Impact factor: 4.130

3.  Treatment Patterns and Outcomes of Elderly Patients With Potentially Curable Esophageal Cancer.

Authors:  Yang Yang; Mengyuan Chen; Jiping Xie; Yongling Ji; Liming Sheng; Guoqin Qiu; Xianghui Du; Qichun Wei
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

4.  Treatment disparities affect outcomes for patients with stage I esophageal cancer: a national cancer data base analysis.

Authors:  Amy C Moreno; Ning Zhang; Vivek Verma; Sharon H Giordano; Steven H Lin
Journal:  J Gastrointest Oncol       Date:  2019-02

5.  Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Gastrointest Oncol       Date:  2018-02

6.  Utilization of neoadjuvant intensity-modulated radiation therapy and proton beam therapy for esophageal cancer in the United States.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Gastrointest Oncol       Date:  2018-04

7.  Utilization of intensity modulated radiation therapy for anal cancer in the United States.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Gastrointest Oncol       Date:  2018-06

8.  Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base.

Authors:  Vivek Verma; Adams Kusi Appiah; Tim Lautenschlaeger; Sebastian Adeberg; Charles B Simone; Chi Lin
Journal:  J Gastrointest Oncol       Date:  2018-06

Review 9.  The Role of Radiation Therapy in the Older Patient.

Authors:  Ammoren Dohm; Roberto Diaz; Ronica H Nanda
Journal:  Curr Oncol Rep       Date:  2021-01-02       Impact factor: 5.075

10.  Chemotherapy Versus Chemoradiation for Node-Positive Bladder Cancer: Practice Patterns and Outcomes from the National Cancer Data Base.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  Bladder Cancer       Date:  2017-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.